These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 31279304)

  • 61. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
    Tabouret E; Houillier C; Martin-Duverneuil N; Blonski M; Soussain C; Ghesquières H; Houot R; Larrieu D; Soubeyran P; Gressin R; Gyan E; Chinot O; Taillandier L; Choquet S; Alentorn A; Leclercq D; Omuro A; Tanguy ML; Hoang-Xuan K
    Neuro Oncol; 2017 Mar; 19(3):422-429. PubMed ID: 27994065
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
    Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
    Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
    Jahnke K; Korfel A; Komm J; Bechrakis NE; Stein H; Thiel E; Coupland SE
    Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):663-9. PubMed ID: 16228920
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
    Pentsova E; Deangelis LM; Omuro A
    J Neurooncol; 2014 Mar; 117(1):161-5. PubMed ID: 24481997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes.
    Lim T; Kim SJ; Kim K; Lee JI; Lim DH; Lee DJ; Baek KK; Lee HY; Han B; Uhm JE; Ko YH; Kim WS
    Ann Hematol; 2011 Dec; 90(12):1391-8. PubMed ID: 21479535
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
    Chamberlain MC
    J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
    J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.
    Zhang JP; Lee EQ; Nayak L; Doherty L; Kesari S; Muzikansky A; Norden AD; Chen H; Wen PY; Drappatz J
    J Neurooncol; 2013 Oct; 115(1):71-7. PubMed ID: 23828279
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
    Iwadate Y; Suganami A; Ikegami S; Shinozaki N; Matsutani T; Tamura Y; Saeki N; Yamanaka R
    J Neurooncol; 2014 Apr; 117(2):261-8. PubMed ID: 24488444
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
    Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
    Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 79. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
    Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
    Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.